Cohance Lifesciences Limited
Hyderabad based CDMO company that offers services to leading global pharmaceutical and fine chemical majors in their NCE development endeavours. From process research & development to late-stage clinical and commercial manufacturing we are committed to provide customers with products fulfilling customer needs and expectations.
What Cohance files
- Investor Meet53
- Others52
- Updates27
- Important20
- PPTs7
- Board Meeting7
Cohance Lifesciences' Shamshabad plant received 4 USFDA observations after an inspection. The company has initiated corrective actions and will respond, reaffirming its commitment to quality and compliance.
Cohance Lifesciences advances its ADC strategy with a USD 13 million additional investment in NJ Bio and a USD 5 million controlling investment in Aruka Bio. This reorganisation, funded by internal accruals, strengthens integration and pipeline development.
Cohance Lifesciences paid a ₹8.30 Cr RBI compounding fee for a past forex violation. Operationally, the company made strides in FY26, reducing energy intensity by 16.9% and Scope 1&2 GHG by 18.9%. Zero Liquid Discharge is implemented at multiple units. Exports contribute 84% of turnover.
Cohance Lifesciences completed its merger, expanding its CRDMO platform. This year, revenue hit ₹2,269 Cr, Adjusted EBITDA ₹477 Cr, and net cash ₹153 Cr. Expect continued growth from new commercial orders, especially in ADC/Oligo. Nacharam facility received a US FDA Warning Letter; minor filing delay also noted.
Cohance Lifesciences' USFDA inspection at its Hyderabad facility concluded with five observations. Importantly, none relate to data integrity issues. The company is preparing corrective actions and expects timely resolution of these observations.